These authors contributed equally to this work.
Short Report: Epidemiology
The humoral immune response to the inactivated influenza A (H1N1) 2009 monovalent vaccine in patients with Type 2 diabetes mellitus in Korea
Article first published online: 15 JUN 2011
© 2011 The Authors. Diabetic Medicine © 2011 Diabetes UK
Volume 28, Issue 7, pages 815–817, July 2011
How to Cite
Nam, J. S., Kim, A. R., Yoon, J. C., Byun, Y., Kim, S. A., Kim, K. R., Cho, S., Seong, B. L., Ahn, C. W. and Lee, J. M. (2011), The humoral immune response to the inactivated influenza A (H1N1) 2009 monovalent vaccine in patients with Type 2 diabetes mellitus in Korea. Diabetic Medicine, 28: 815–817. doi: 10.1111/j.1464-5491.2011.03255.x
- Issue published online: 15 JUN 2011
- Article first published online: 15 JUN 2011
- Accepted manuscript online: 5 FEB 2011 03:18PM EST
- Accepted 19 January 2011
Vol. 28, Issue 12, 1541, Article first published online: 17 NOV 2011
- antibody seroconversion;
- influenza A (H1N1) 2009 monovalent vaccine;
- Type 2 diabetes mellitus
Diabet. Med. 28, 815–817 (2011)
Aims We evaluated the antibody response to a single-dose adjuvanted, inactivated, pandemic H1N1 influenza vaccination in patients with diabetes and assessed factors associated with the failure to induce antibody responses.
Methods Eighty-two patients with Type 2 diabetes were vaccinated and antibody responses were determined with haemagglutination inhibition assay and anti-haemagglutinin antibody ELISA.
Results Among 70 antibody-negative patients at baseline, 34 (48.6%) achieved seroconversion; 28 (60.9%) in the young adults group and six (25%) in the elderly group acquired H1N1-specific antibodies. Patients in the older age range or with longer duration of diabetes had a lower seroconversion rate.
Conclusions Our data show low cross-reactive antibody carrying rate and low seroconversion rate in patients with diabetes. Until larger-scale, case-controlled trials become available, older patients and patients with a longer duration of diabetes should be considered for the two-dose vaccination or have antibody titres measured after the first vaccination.